Business
Armata is a late clinical-stage biotechnology company developing high-purity pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.
Armata remained pre-revenue, the net loss widened to $173.8M, but free cash flow improved to -$26.3M.
The read at a glance✓ Audited against SEC data
- Business mix — Bacteriophage therapeuticsNote
- Revenue — No standard revenue fieldNote
- Profitability — Net loss widened to $173.8MWatch
- Cash — FCF improved to -$26.3MNote
- Balance sheet — Equity fell to -$218.6MWatch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Forensic screen unavailableNote
Leadership changes
From Armata Pharmaceuticals, Inc.'s own filings, the day they're filed.
- Daniel Gilmer · Directors · appointmenteff. 2026-04-24
- Deborah Birx · Chief Executive Officer · departureeff. 2023-07-11
- Brian Varnum · Chief Executive Officer · departureeff. 2023-07-10
Latest filings
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-07-20
- 8-K · Company announcement2026-07-20
- 8-K · Company announcement2026-07-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Armata Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.